Stroke. Diagnosis and therapeutic management of cerebrovascular disease;Ictus. Diagnóstico y tratamiento de las enfermedades cerebrovasculares

Revista Espanola de Cardiologia

Volumn 60, Issue 7, 2007, Pages 753-769

  Ustrell Roig, Xavier ^a   Serena Leal, Joaquín ^b  

^a Hospital de Sant Pau i Santa Tecla   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Cerebrovascular diseases; Stroke; Stroke units; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ATENOLOL; ATORVASTATIN; CITICOLINE; CLOPIDOGREL; DESMOTEPLASE; DIPYRIDAMOLE; EPROSARTAN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LOSARTAN; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; SERENIC AGENT; TICLOPIDINE; TRIFLUSAL; WARFARIN;

ANGIOPLASTY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; EMBOLISM; FOOD AND DRUG ADMINISTRATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHERMIA; LYSIS; MEDICAL LITERATURE; MORTALITY; NEUROIMAGING; NEUROPROTECTION; PATHOGENESIS; PATIENT SELECTION; PREVENTIVE MEDICINE; REVIEW; RISK REDUCTION; STROKE; SURGICAL TECHNIQUE; ULTRASOUND; CEREBROVASCULAR ACCIDENT;

CEREBROVASCULAR ACCIDENT; HUMANS;

EID: 34548008346     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13108281     Document Type: Article

References (91)

1. Arboix A, Álvarez-Sabín J, Soler L, en nombre del en nombre del Comité de redacción ad hoc del Grupo de estudio de Enfermedades Cerebrovasculares de la SEN. Ictus. Tipos etiológicos y criterios diagnósticos. Neurología. 1998;13 Suppl 3:4-10.
2. Arboix A, Díaz J, Pérez-Sempere A, Álvarez- Sabín J, en nombre del Comité de redacción ad hoc del Grupo de estudio de Enfermedades Cerebrovasculares de la SEN. Ictus. Tipos etiológicos y criterios diagnósticos. Neurología. 2002;17 Suppl 3:3-12.
3. Álvarez-Sabín J. Etiopatogenia de la isquemia cerebral focal. En: Castillo J, Martínez-Vila E, editores. Trombosis, fármacos antitrombóticos y enfermedad cerebrovascular. Barcelona: Uriach & Cia., 1995. p. 381-409.
4. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet. 1999;354:1457-63.
5. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817-20.
6. Johnston SC, Gress DR, Browner WS, Sidney S. Short term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901-6.
7. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, et al for the TIA working group. Transient ischemic attack-proposal for a new definition. N Eng J Med. 2002;347:1713-6.
8. Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares. Guía para el diagnóstico y tratamiento del ictus. Guías oficiales de la Sociedad Española de Neurología No 3. Barcelona: Prous Science, S.A.; 2006.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
10. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol. 2005;58:688-97.
11. Dávalos A, Castillo J, Martínez-Vila E, for the Cerebrovascular Disease Study Group of the Spanish Society of Neurology. Delay in neurological attention and stroke outcome. Stroke. 1995;26:2233-7.
12. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology. 1993;43:461-7.
13. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35:520-7.
14. Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996;347:422-5.
15. Castillo J, Dávalos A, Marrugat J, Noya M. Timing for fever related brain damage in acute ischemic stroke. Stroke. 1998;29:2455-60.
16. Baird TA, Parsons MW, Phanh T, Butcher KS, Desmond PM, Tress BM, et al. Persistent poststroke hyperglycemia is independently asociated with infarct expansion and worse clinical outcome. Stroke. 2003;34:2208-14.
17. Davalos A, Ricart W, González-Huix F, Soler S, Marrugat J, Molins A, et al. Effect of malnutrition after acute stroke on clinical outcome. Stroke. 1996;27:1028-32.
18. Strand T, Asplund K, Eriksson S, Hagg E, Lithner F, Wester PO, et al. A non intensive stroke unit reduces funtional disability and the need for long term hospitalization. Stroke. 1985;16:29-34.
19. Strand T, Asplund K, Eriksson S, Haag E, Lithner F, Wester PO, et al. Stroke unit care. Who benefits? Comparisons with general medical care in relation to prognostic indicators on admission. Stroke. 1986;17:377-81.
20. Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim LL, Holme I. Benefit of stroke unit: a randomized controlled trial. Stroke. 1991;22:1026-31.
21. Hommel M, Memin B, Besson G, Perret J. Hospital admission and acute stroke unit. Cerebrovasc Dis. 1991;1 Suppl 1:50-3.
22. Langhorne P, Willians BO, Gilchrist W, Howie K. Do stroke units save lives? Lancet. 1993;342:395-8.
23. Silva Y, Puigdemont M, Castellanos M, Serena J, Suñer RM, García MM, et al. A semi-intensive monitoring in acute stroke and long-term outcome. Cerebrovasc Dis. 2005;19:23-30.
24. Stroke Unit Triallists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2002;(1):CD000197.
25. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-82.
26. The National Institute of Neurological Disorders and Stroke rtPA Study Group (NINDS). Tissue plasminogen activator for acute ischemic stroke. N Eng J Med. 1995;333:1581-7.
27. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-50.
28. Dávalos A, Álvarez-Sabín J, Martí-Vilalta JL, Castillo J, por el Registro de Trombólisis del Grupo de Estudio de las Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Proyecto ICTUS. Tratamiento intravenoso con activador del plasminógeno tisular en la isquemia cerebral aguda. Med Clin (Barc). 2003;120:1-5.
29. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-25.
30. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-50.
31. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-11.
32. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-605.
33. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-81.
34. Chinese Acute Stroke Trial (CAST). randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1999;349:1641-9.
35. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-51.
36. Butenas S, Cawthern KM, Van't Veer C. Antiplatelet agents in tissue factor-induced blood coagulation. Blood. 2001;97:2314-22.
37. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. 2005;36:880-90.
38. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
39. Smith WS, Sung S, Starkman S, Saber JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI Trial. Stroke. 2005;36:1432-8.
40. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. Am J Neuroradiol. 2006;27:1177-82.
41. Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS, for the MERCI and Multi Merci writing committee. Mechanical Thromectomy of Intracranial carotid occlusion. Pooled results of the MERCI and multiMERCI Part I trials. Stroke. 2007. En prensa.
42. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Álvarez-Sabin J, et al. For the CLOTBUST investigators. Ultrasound. enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170-8.
43. Dávalos A, Castillo J, Álvarez-Sabin J, Secades JJ, Mercader J, López S, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-7.
44. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypotermia to improve neurological outcome after cardiac arrest. N Engl J Med. 2002;346:549-56.
45. Krieger D, De Georgia M, Abou-Chebl A. Cooling for acute ischemic brain damage (COOLAID). Stroke. 2001;32:1847-54.
46. Giorgadis D, Schwarz S, Kollmar R, Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: firts results of a novel aproach. Stroke. 2001;32:2550-3.
47. Feinberg WM. Primary and secodary stroke prevention. Curr Opin Neurol. 1996;9:46-52.
48. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke at high risk patients. BMJ. 2002;324:71-86.
49. Algra A, Van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255.
50. The Dutch TIA study group: a comparison of tw doses of aspirin (30mg vs 283mg a day) in patients after transient ischaemic attack or minor stroke. N Engl J Med. 1991;54:1044-54.
51. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psyquiatry. 1991;54:1044-54.
52. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for Prevention of Stroke in Patients with ischaemic stroke or transeint ischaemic attack: A statement for healthcare professionals from the American Heart Association/ American Stroke Association Council on Stroke. Stroke. 2006;37:577-617.
53. Hacke W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, et al; European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for stroke management-update 2003. Cerebrovasc Dis. 2003;16:311-37.
54. CAPRIE Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. (CAPRIE). Lancet. 1996;348:1329-39.
55. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, for the CAPRIE investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35:528-32.
56. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7.
57. Secondary prevention in non-rheumatic atrial fibrillation after trasnient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62.
58. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8.
59. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-31.
60. Serena J. Patent foramen ovale. What is it and what does' it indicate? Neurologia. 2006;21:689-94.
61. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboembolia: a systematic review. Ann Intern Med. 2003;139:753-60.
62. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003;34:2741-9.
63. Lawes CM, Bennet DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:776-85.
64. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertin-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:144-53.
65. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 patients with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41.
66. Dahlöf B, Devereux R, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a ranomised trial against atenolol. Lancet. 2002;359:995-1003.
67. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan compared with nitrendipine for Secondary prevention (MOSES). Stroke. 2005;36:1218-26.
68. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
69. Crouse JR III, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trial data. Atherosclerosis. 1998;138:11-24.
70. Ross SD, Allen IE, Connelly JE, Korenblatt BM, Smith ME, Bishop D, et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159:1793-802.
71. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-20.
72. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med. 2006;355:549-59.
73. European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351:1379-87.
74. North American Symptomatic Carotid Endarterectomy Trialists' Collaborative Group. The final results of the NASCET trial. N Engl J Med. 1998;339:1415-25.
75. CAVATAS investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet. 2001;357:1729-37.
76. Gil-Peralta A. Utilidad de la endarterectomía carotídea y de la angioplastia transluminal percutánea en el tratamiento de las estenosis arteriales. Neurología. 2001;16 Supl 3:119-23.
77. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273:1421-8.
78. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al, for the MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:1491-502.
79. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. An invited review. Stroke. 2002;33:862-75.
80. Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry. 1994;57:936-40.
81. Counsell C, Boonyakarnkul S, Dennis M, Sandercock P, Bamford J, Burn J, et al. Primary intracerebral haemorrhage in the Oxfordshire Community Stroke Project, 2: prognosis. Cerebrovasc Dis. 1995;5:26-34.
82. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The stroke data bank: design, methods and baseline characteristics. Stroke. 1988;19:547-54.
83. Brott N, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke. 1986;17:1078-83.
84. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. Stroke. 1996;27:1783-7.
85. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients wuth intracerebral hemorrhage. Stroke. 1997;28:1-5.
86. Castillo J, Davalos A, Álvarez-Sabin J, Pumar JM, Leira R, Silva Y, et al. Molecular signatures of brain injury after cerebral hemorrhage. Neurology. 2002;58:624-9.
87. Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, García M, et al; Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. Early neurological deterioration in intracreberal hemorrhage: predictors and asociated factors. Neurology. 2004;63:461-7.
88. Mayer S, Brun N, Broderick J, Davis S, Diringer M, Skolnick B, et al. Europe/Australasian NovoSeven ICH Trial Investigators: recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
89. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults. 2007 Update. A Guideline From the American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007. En prensa.
90. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34:224-9.
91. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STITCH): a randomised trial. Lancet. 2005;365:387-97.